Koga Makoto, Aoki Masatora, Anegawa Emiko, Tezuka Makoto, Iwamoto Osamu, Koga Chihiro, Kusukawa Jingo
Dental and Oral Medical Center, Kurume University School of Medicine.
Gan To Kagaku Ryoho. 2007 May;34(5):719-23.
The purpose of this study was to investigate the effectiveness and safety of palliative chemotherapy using S-1. We treated 19 advanced oral SCC patients including 8 men and 11 women with S-1. Of the 19 patients studied, two patients were classified as UICC Stage II, two patients as Stage III, 14 patients as Stage IV A, and one patient was classified as StageIV C. The ages varied from 54 to 9 1 years (mean ages; 78.3 years-old). The patients received this chemotherapy (80-120 mg/day) consisting of 2 weeks' administration including 5-days' administration and 2-days' termination (named 'Weekday-on/Weekend-off administration schedule' ) following 1 week rest. After this treatment, 7 CR and 4 PR were achieved, but the toxicities were only anorexia, leukopenia, thrombocytopenia, and uritication of NCI-CTC grade 1. The prognosis of 19 cases was 7 terminal by primary disease, 3 terminal by other disease, 7 lives with tumor bearing, and 2 lives without tumor bearing. We concluded that our novel S-1 administration method was extremely effective for oral SCC, including lymph node metastasis, providing high potential without any severe adverse effects for palliative therapy.
本研究的目的是调查使用S-1进行姑息性化疗的有效性和安全性。我们用S-1治疗了19例晚期口腔鳞状细胞癌患者，其中男性8例，女性11例。在19例研究患者中，2例被分类为国际抗癌联盟（UICC）II期，2例为III期，14例为IV A期，1例为IV C期。年龄从54岁到91岁不等（平均年龄；78.3岁）。患者接受这种化疗（80 - 120毫克/天），采用2周给药方案，包括5天给药和2天停药（称为“工作日给药/周末停药给药方案”），之后休息1周。经过这种治疗，实现了7例完全缓解（CR）和4例部分缓解（PR），但毒性仅为美国国立癌症研究所常见毒性标准（NCI-CTC）1级的厌食、白细胞减少、血小板减少和排尿困难。19例患者的预后情况为，7例因原发性疾病死亡，3例因其他疾病死亡，7例带瘤生存，2例无瘤生存。我们得出结论，我们新颖的S-1给药方法对包括淋巴结转移在内的口腔鳞状细胞癌极为有效，为姑息治疗提供了高潜力且无任何严重不良反应。
